Company Directory - GeneDx Holdings Corp.
Company Details - GeneDx Holdings Corp.
GeneDx Holdings Corp.
WebsiteGeneDx is a genomics company that specializes in providing genomic information and testing services for healthcare. Their offerings are designed to aid in the diagnosis and management of genetic conditions, helping healthcare professionals make informed decisions regarding patient care.
CCI Score
CCI Score: GeneDx Holdings Corp.
-37.82
0.16%
Latest Event
Investigation into Fraudulent Business Practices at GeneDx
GeneDx Holdings is under investigation by Pomerantz LLP following allegations of securities fraud, illegal billing practices ('code stacking'), and suspicious insider trading by top executives, which have led to a significant drop in stock price.
Take Action
So what can you do? It's time to make tough choices. Where will you cast your vote?
- Shop Alternatives
SEE ALL - Use Your Voice
OTHER TOOLS - Investigate
- Share the Score
SUPPORT CCI
TOADIE
GeneDx Holdings Corp. is currently rated as a Toadie.
Latest Events
- FEB182025
GeneDx Holdings is under investigation by Pomerantz LLP following allegations of securities fraud, illegal billing practices ('code stacking'), and suspicious insider trading by top executives, which have led to a significant drop in stock price.
-40
Business Practices and Ethical Responsibility
April 30
The investigation into GeneDx centers on allegations of fraudulent behavior, including illegal billing practices and suspicious insider trading by executives. Such unethical business practices undermine investor trust and corporate accountability, contributing indirectly to broader issues of economic injustice which can empower authoritarian corporate behavior.
GeneDx Holdings Faces Serious Allegations Amid Class Action Investigations
- FEB102025
An investigation has been launched into GeneDx Holdings Corp. following allegations of fraudulent revenue inflation tactics, including code stacking and illegal insider sales by top executives. The report claims that these unethical practices have artificially inflated the company’s revenue and led to a significant stock price decline.
-70
Business Practices and Ethical Responsibility
April 30
The investigation details alleged fraudulent schemes, including artificially inflated revenue through illegal billing practices and suspicious insider trading by executives. These practices undermine corporate transparency and ethical responsibility, posing significant risks to investor trust and overall corporate governance.
- DEC312022GeneDx Engages in Lobbying
-31.41
In 2022, GeneDx spent $67,500 on lobbying by hiring external firms, as reported by OpenSecrets. This expenditure illustrates the company's active involvement in political influence, which may prioritize corporate interests over broader progressive and anti-fascist values.
-40
Political Contributions and Lobbying Efforts
April 30
The lobbying expenditure of $67,500 in 2022 indicates that GeneDx is investing in political influence through external lobbying firms. Such activity is concerning from an anti-fascist perspective as it can be a tool for advancing corporate interests that may undermine progressive policies and worker rights.
- DEC312022
According to OpenSecrets data, GeneDx spent $67,500 on lobbying activities during 2022. This expenditure reflects the company's engagement in political lobbying, which can contribute to corporate influence over policymaking and undermine democratic accountability.
-20
Political Contributions and Lobbying Efforts
April 30
The $67,500 spent on lobbying in 2022 demonstrates GeneDx’s active participation in shaping political outcomes. Such corporate lobbying efforts, even at a moderate level, risk aligning business interests with policies that may favor entrenched power structures and weaken anti-authoritarian, democratic processes.
- DEC312022
GeneDx Inc spent $67,500 lobbying in 2022, as reported by OpenSecrets. The lobbying efforts focused on issues related to Medicare & Medicaid, reflecting corporate attempts to influence public policy.
-40
Political Contributions and Lobbying Efforts
April 30
GeneDx's lobbying expenditure of $67,500 in 2022 indicates an engagement in political lobbying aimed at influencing healthcare policy. This form of political spending, while common, raises concerns about corporate influence on public policy and democratic accountability, aligning with concerns about entrenched corporate power influencing political processes.
- AUG162022
A lawsuit filed by investor Steven Scinto alleges that GeneDx (formerly Sema4) engaged in poor corporate governance by overstating growth figures, reversing $30.1 million in revenue, and cutting hundreds of jobs, resulting in a drastic fall in stock price and Nasdaq noncompliance.
-60
Business Practices and Ethical Responsibility
April 30
The misrepresentation of growth data, reversal of significant revenue, and job cuts point to severe ethical lapses in business practices. These actions undermine investor trust and weakens corporate accountability, aligning poorly with ethical responsibility.
-50
Labor Relations and Human Rights Practices
April 30
The drastic reduction in workforce, with hundreds of jobs eliminated, showcases a blatant disregard for worker welfare and fair labor practices, which directly hurts the rights and livelihoods of employees.
Alternatives
Fort Myers, United States
20.21
Belgium (Ghent), Belgium
78.10
Raleigh, USA
55.85
Somerset, United States
1.17
Moradabad, India
0.00
Cranbury, United States
-14.96
Basel, Switzerland
-19.51
Sunnyvale, United States
-32.62
Seattle, United States
-37.70
Toronto, Canada
-43.23
Industries
- 621511
- Medical Laboratories
- 621512
- Diagnostic Imaging Centers
- 541711
- Research and Development in Biotechnology